AstraZenica Group (NYSE:AZN) will partner with Charles River Laboratories International (NYSE:CRL) for in vivo biology, which will permit the former to create a “flexible research platform.” The arrangement will last three years and should to contribute about 1 percent to the latter’s total net sales next year.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Pfizer (NYSE:PFE) reports that a Phase 3 study of Inlyta did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival, compared to sorafenib, in treatment-naive patients suffering from advanced renal cell carcinoma. A preliminary review of the data indicated that overall the median PFS for Inlyta was greater than the median PFS for sorafenib, but did not meet statistical significance.
St. Jude Medical (NYSE:STJ) shares moved down on word that it might receive an FDA warning letter regarding its manufacturing facility in Sylmar, California in which it produces defibrillators and pacemakers. Chief Executive Dan Starks announced the warning possibility on an earnings call, which might not surprise many observers given the huge insulation problems that St. Jude has experienced with the wires for its defibrillators.